Susquehanna International Group
CLRBZ

Susquehanna International Group’s Cellectar Biosciences, Inc. Series A Warrants CLRBZ Stock Holding History

Susquehanna International Group’s Portfolio CLRBZ Stock Details CLRBZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-30,498
Closed -$4K – 12019
2020
Q3 		$4K Buy
+30,498
New +$4.03K ﹤0.01% 10452
2018
Q2 		– Sell
-12,272
Closed -$5K – 10747
2018
Q1 		$5K Sell
12,272
-195,528
-94% -$95.8K ﹤0.01% 9199
2017
Q4 		$104K Sell
207,800
-19,000
-8% -$11.8K ﹤0.01% 8675
2017
Q3 		$148K Sell
226,800
-18,700
-8% -$10.9K ﹤0.01% 8207
2017
Q2 		$147K Sell
245,500
-4,500
-2% -$2.83K ﹤0.01% 8505
2017
Q1 		$228K Sell
250,000
-15,000
-6% -$9.61K ﹤0.01% 7827
2016
Q4 		$111K Buy
+265,000
New +$148K ﹤0.01% 9032

Other funds holding CLRBZ

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Susquehanna International Group's CLRBZ Position: Q4 2020 in Review

Susquehanna International Group sold out of Cellectar Biosciences, Inc. Series A Warrants (CLRBZ) in Q4 2020, closing a stake of 30,498 shares — an estimated $4K sold.

Susquehanna International Group first reported a position in CLRBZ in Q4 2016 and held it in 7 quarters. The position peaked at $228K in Q1 2017. 3 funds tracked by Wall St. Rank hold CLRBZ as of Q4 2020.

  • Susquehanna International Group reported no remaining Cellectar Biosciences, Inc. Series A Warrants position as of Q4 2020 after selling out during the quarter.
  • Susquehanna International Group sold 30,498 Cellectar Biosciences, Inc. Series A Warrants shares in Q4 2020, an estimated $4K.
  • Susquehanna International Group first reported a position in Cellectar Biosciences, Inc. Series A Warrants in Q4 2016 and held it in 7 quarters.
  • Susquehanna International Group's Cellectar Biosciences, Inc. Series A Warrants position peaked at $228K in Q1 2017.
  • 3 funds tracked by Wall St. Rank held Cellectar Biosciences, Inc. Series A Warrants as of Q4 2020.

Based on Susquehanna International Group's 13F filing for Q4 2020, filed 16 Feb 2021.